--:-- ET
Home›ETF directory›497510
ETF analysis

ACE 글로벌빅파마 (497510) holdings & weights

Per-holding contribution · concentration · sector skew — a deep read

KR-listedAs of 2026-10-20
IndexSolactive Global Big Pharma Index (Price Return)
Annual fee0.3%
Net assetsKRW 8.92B
Inception2024-11-19

Fund overview

This is a Korea-listed ETF from 한국투자신탁운용. It tracks the Solactive Global Big Pharma Index (Price Return). Key facts — expense ratio 0.3%; net assets about KRW 8.92B; inception 2024-11-19. Its 1-year return is +20.58%.

Index tracked
Solactive Global Big Pharma Index (Price Return)
Provider
한국투자신탁운용
Expense ratio
0.3%
Net assets (AUM)
KRW 8.92B
Inception
2024-11-19
1-month return
-1.4%
1-year return
+20.58%
Dividend yield
2.27%
Holdings
15
52-week range
10,485–14,990
Fund details

Fund overview

This is a Korea-listed ETF from 한국투자신탁운용. It tracks the Solactive Global Big Pharma Index (Price Return). Key facts — expense ratio 0.3%; net assets about KRW 8.92B; inception 2024-11-19. Its 1-year return is +20.58%.

Index tracked
Solactive Global Big Pharma Index (Price Return)
Provider
한국투자신탁운용
Expense ratio
0.3%
Net assets (AUM)
KRW 8.92B
Inception
2024-11-19
1-month return
-1.4%
1-year return
+20.58%
Dividend yield
2.27%
Holdings
15
52-week range
10,485–14,990

15 identified stocks · net exposure / NAV 100.00%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.

Weight and calculation basis

15 identified stocks · net exposure / NAV 100.00%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.

Investor net buying

Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).

0 sh
Foreign
0 sh
Institution
−70 sh
Retail
0%
Foreign ownership
DateChangeForeignInst.Retail
10/20-0.71%0 sh0 sh−70 sh
10/19-0.28%0 sh+7.7K sh−322 sh
10/16+0.47%0 sh−550 sh+550 sh
10/15+3.77%0 sh−7.9K sh+929 sh
10/14-2.67%0 sh−25 sh+25 sh
Investor flows

Investor net buying

Latest-session net buying by foreigners, institutions and retail (positive = net buy, negative = net sell).

0 sh
Foreign
0 sh
Institution
−70 sh
Retail
0%
Foreign ownership
DateChangeForeignInst.Retail
10/20-0.71%0 sh0 sh−70 sh
10/19-0.28%0 sh+7.7K sh−322 sh
10/16+0.47%0 sh−550 sh+550 sh
10/15+3.77%0 sh−7.9K sh+929 sh
10/14-2.67%0 sh−25 sh+25 sh
—
Holdings not priced
87.3%
Top-10 weight
1045
Concentration HHI (Low)
Health Care
Top sector

We have this ETF's holdings, but the prices for those particular listings are outside our quote coverage (currently Korea- and US-listed securities). So today's contribution and return are not computed — showing 0% would claim it did not move, which is a different statement. The holdings and weights below follow the calculation basis above.

Today's summary

Its top 10 holdings make up about 87.3% of the fund. The concentration index (HHI) is 1045 — Low — evenly diversified, and the largest sector is Health Care (93%). The higher the concentration, the more one stock or sector drives the whole ETF's return.

Structural health

A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.

50/ 100
CTilted structure
DiversificationHHI 1,04552

Concentration is below 1,500 (1,045), so no single holding dominates.

Sector balanceHealth Care 93%0

Health Care alone is 93%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.

Cost0.3%/yr78

0.3% a year is typical. Held ten years, roughly 3.0% goes to fees.

Fund sizeKRW 8.9B0

Net assets of KRW 8.9B are small. Thin funds trade at wider spreads, and very small ones get closed or merged.

Structural simplicityPhysical, 1x100

A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.

Concentration and diversification

Structural health

A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.

50/ 100
CTilted structure
DiversificationHHI 1,04552

Concentration is below 1,500 (1,045), so no single holding dominates.

Sector balanceHealth Care 93%0

Health Care alone is 93%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.

Cost0.3%/yr78

0.3% a year is typical. Held ten years, roughly 3.0% goes to fees.

Fund sizeKRW 8.9B0

Net assets of KRW 8.9B are small. Thin funds trade at wider spreads, and very small ones get closed or merged.

Structural simplicityPhysical, 1x100

A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.

Top 15 holdings

Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.

Normalized to 100% of analysed positions

Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.

Tile size = weight, colour = the day's return (deeper = larger). Covers the top 15 holdings, 100.0% of the fund. Labels are dropped where a tile is too small; hover any tile for its name and figures.
#HoldingWeight
1ELI LILLYLLY20.06%
2JOHNSON & JOHNSONJNJ14.43%
3ABBVIEABBV12.17%
4MERCKMRK8.12%
5RocheROP SW7.15%
6NovartisNVS7.01%
7ASTRAZENECA-SPAZN5.59%
8AMGENAMGN4.99%
9GILEAD SCIENCESGILD4.46%
10PFIZERPFE3.32%
11Vertex PharmaceuticalsVRTX3.14%
12Novo Nordisk A/SNVO2.85%
13SanofiSNY2.29%
14GSKGSK2.23%
15BRISTOL-MYERS SQUIBBBMY2.19%

Holdings below 0.5% or outside the top list are folded into “Others” and omitted above.

Where the weight sits — sector mix

Listed equity weights summed by sector and normalized to 100%. Each band is one sector's share.

Health Care92.8%
Unclassified7.2%
Industry breakdown
Biotechnology: Pharmaceutical Preparations83.4%
Biotechnology: Biological Products (No Diagnostic Substances)9.4%
Unclassified7.2%
Concentration at a glanceHHI 1,045moderate
spread1,0001,8002,500concentrated

HHI sums the squared weights. The more it leans on a few names, the higher it goes — and the more the whole ETF moves with them.

How concentrated is it

Concentration (HHI) sits at 1045 — moderate. The top 10 names carry 87.3% of equity weight, so the fund is spread out but its largest holdings still steer it.

That is the usual shape of a cap-weighted index fund: broad, yet tilted toward the biggest companies.

HHI squares each weight and sums them: 10,000 means one stock is everything, and the more evenly spread the holdings, the closer it falls to zero.

Where the sector weight sits

By sector, Health Care alone is 93% — whatever the fund is called, this is a bet on that industry.

Bad news for the sector moves the whole fund. Worth checking against anything else you hold in the same space.

Weights above sum the individually listed equities and normalize that equity total to 100%.

How much it overlaps others

It shares 63% of its holdings with 476690 (8 names in common) — close to half the same companies.

Own both and the diversification is thinner than it looks.

What it is made of

The expense ratio is 0.3% a year. Funds tracking the same index tend to perform alike, which makes the fee one of the few things that reliably separates them over time.

This page is not investment advice. Investment decisions and responsibility are your own.

497510 comments

Leave a one-line take on ACE 글로벌빅파마. No account — just a nickname and a code to delete it later.

Loading…

Similar ETFs

Picked by how much their actual holdings overlap. The higher the overlap, the less diversification you get from owning both.